Introduction Patients with asthma typically increase short-acting β 2-agonists (SABA) use
with worsening symptoms. Excessive SABA use may lead to a higher risk of adverse …

Background Overuse of short-acting β 2-agonists (SABA) may indicate poor asthma control
and adverse health outcomes. Contemporary population-based data on use, risk factors and …

Background To gain a global perspective on short-acting β2-agonist (SABA) prescriptions
and associated asthma-related clinical outcomes in patients with asthma, we assessed …

Background Expert national/global asthma management recommendations raise the issue
whether a safe threshold of short-acting beta-2 agonist (SABA) use without concomitant …

Introduction Globally, individuals with asthma tend to overrely on short-acting β 2-agonists
(SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying …

As SABA overuse is associated with exacerbations and mortality, GINA no longer
recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA …

Background Inappropriate use of short-acting beta-agonists (SABA) has been associated
with increased morbidity and mortality in asthma. However, the extent and pattern of SABA …

Despite the availability of effective asthma treatments, some patients are poorly controlled
because of overreliance on short-acting β 2-agonists (SABAs) and underuse of inhaled …

For years, standard asthma treatment has included short acting beta agonists (SABA),
including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for …

Short-acting β2 agonists (SABAs) have been a mainstay of asthma treatment since the
1950s, and have been mainly recommended as-needed for symptom relief alongside daily …